EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China

Wenwang Lang iD, Jiangbo Wang, Ming Ouyang, Haiqing Zhao, Tingting Zhou, Lingyue Huang

PLOS One · 2025

DOI: 10.1371/journal.pone.0331338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Wenwang Lang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Quinolines, Lung Neoplasms, Indoles. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Drug clinical comprehensive evaluation project of Health Commission of Guangxi Zhuang Autonomous Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Benmelstobart combined with anlotinib and chemotherapy has demonstrated significant clinical advantages in extending progression-free survival and overall survival compared to chemotherapy alone in patients with extensive-stage small-cell lung cancer (ES-SCLC). This is the first study to assess its cost-effectiveness from both the US payer and Chinese healthcare system perspectives.

Method

A Markov state-transition model was utilized for the economic evaluation, reflecting both the perspectives of the US payer and the Chinese healthcare system. Baseline patient demographics and vital clinical data were obtained from the ETER701 trial. Costs and utilities were obtained from open-access databases and published literature. The primary outcomes evaluated were quality-adjusted life years (QALYs), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB). The uncertainties of the model were addressed through probabilistic sensitivity analysis, one-way sensitivity analysis, and scenario analysis.

Results

In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. This exceeds the willingness-to-pay (WTP) threshold of $38,042.49 per QALY in China, making the treatment marginally cost-effective, with an INHB of −0.30 QALYs and an INMB of -$11,561.58. In the US, the treatment resulted in a QALY increase of 0.36, but incurred an additional cost of $151,052.04, leading to an ICER of $416,398.56 per QALY, surpassing the US WTP threshold of $150,000. 00.

Conclusion

The combination of benmelstobart and anlotinib with chemotherapy is not a cost-effective first-line treatment option for ES-SCLC in either China or the US.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaQuinolinesLung NeoplasmsIndolesAntineoplastic Combined Chemotherapy ProtocolsHumansCost-Benefit AnalysisUnited StatesChinaQuality-Adjusted Life YearsFemaleMaleMiddle AgedMarkov ChainsAgedCost-Effectiveness Analysis

Substanzen

QuinolinesanlotinibIndoles

Autor:innen und Institutionen

  • Department of Pharmacy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.

ORCID-Profile: Wenwang Lang

Förderung

  • Drug clinical comprehensive evaluation project of Health Commission of Guangxi Zhuang Autonomous Region

Zitieren

APA

Lang, W., Wang, J., Ouyang, M., Zhao, H., Zhou, T., & Huang, L. (2025). Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China. PLOS One. https://doi.org/10.1371/journal.pone.0331338

Vancouver

Lang W, Wang J, Ouyang M, Zhao H, Zhou T, Huang L. Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China. PLOS One. 2025. doi:10.1371/journal.pone.0331338

BibTeX
@article{Lang2025,
  author = {Lang, Wenwang and Wang, Jiangbo and Ouyang, Ming and Zhao, Haiqing and Zhou, Tingting and Huang, Lingyue},
  title = {Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0331338}
}
Kostenlos starten →